Needle-free Strep A vaccine could be closer to reality than we think

New research by the Medicines and Healthcare products Regulatory Agency (MHRA) has brought a potential needle-free vaccine against Group A Streptococcus (Strep A) a step closer

The study, conducted in partnership with the GSK Vaccines Institute for Global Health and published in Human Vaccines & Immunotherapeutics in October 2026, explores an innovative vaccination approach that could make immunisation easier and more accessible worldwide.

Strep A is a highly contagious bacterium responsible for more than 600 million infections globally each year. While many infections cause mild illnesses, such as sore throats and skin infections, serious complications can lead to long-term disability or death.

Complications associated with Strep A are estimated to contribute to more than 500,000 deaths annually, with low- and middle-income countries particularly affected.

Although Strep A is a significant global health burden, no licensed vaccine currently prevents Strep A infections. Researchers hope an effective vaccine could reduce illness, prevent serious complications, and limit the need for antibiotics.

How could a needle-free vaccine work?

The research focuses on a technology called Generalised Modules for Membrane Antigens (GMMA). These are tiny particles naturally released by bacteria that can be used to carry vaccine components and boost the body’s immune response.

Scientists investigated whether a Strep A vaccine using this technology could be delivered through the nose or under the tongue, rather than by injection.

Unlike conventional vaccines that primarily aim to generate antibodies in the bloodstream, this approach also targets mucosal immunity. This is the body’s defence system at surfaces such as the nose and throat, where Strep A infections often begin.

The study found that the vaccine generated immune responses at these mucosal surfaces and throughout the body, suggesting potential protection against infection and more serious disease.

What do these findings mean

Dr Fatme Mawas, Head of Conjugate Vaccines, MHRA said:

“This approach could make vaccines easier to administer and more accessible globally, particularly in low- and middle-income countries where the burden of Strep A disease is greatest.”

“By preventing infections before they occur, vaccines can also help reduce antibiotic use and support efforts to tackle antimicrobial resistance.”

The findings encourage the development of affordable, easier-to-administer vaccines, particularly in regions where access to healthcare and vaccination services is limited.

A successful vaccine could also help reduce antibiotic use by preventing infections, supporting wider efforts to tackle antimicrobial resistance.
However, researchers conducted the study in mice, and it remains at the pre-clinical stage. Further studies are needed to determine whether the approach is safe and effective in humans.

Although a needle-free Strep A vaccine is not yet available, the research represents a step towards new vaccination methods that could help reduce the global impact of this serious bacterial infection.